Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma

Chinese Journal of Pathology

Volumn 41, Issue 9, 2012, Pages 590-594

  Lino, Yun ^a   Ying, Jian Ming ^a   Qiu, Tian ^a   Shan, Ling ^a   Quo, Lei ^a   Lü, Ning ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Colorectal neoplasms; DNA mutational analysis; Polymerase chain reaction; Sequence analysis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ARTICLE; CODON; COLORECTAL TUMOR; EXON; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84867497326     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.09.004     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
2. Soulieres D, Greer W, Magliocco AM, et al. KKAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol, 2010, 17 Suppl 1:S31-S40.
3. De Roock W, Claes B, Bemasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer; a retrospective consortium analysis. Lancet Oncol, 2010, 11(8):753-762.
4. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26(35):5705-5712.
5. Riely GJ, Ladanyi M. KRAS mutations; an old oncogene becomes anew predictive biomarker. J Mol Diagn, 2008, 10(6):493-495.
6. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 2006, 12(18):5268-5272.
7. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res, 2010, 16(3):790-799.
8. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008, 26(3):374-379.
9. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wildtype state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol, 2008, 19(3):508-515.
10. Wang HL, Lopategui J, Amin MB, et al. KRAS mutation testing in human cancers; The pathologist's role in the era of personalized medicine. Adv Anat Pathol, 2010, 17(1):23-32.
11. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev, 2000, 9(11):1193-1197.
12. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med, 2004, 351(27):2883.
13. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer; a cohort study. Lancet Oncol, 2005, 6(5):279-286.
14. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan; results from the MRC FOCUS trial. J Clin Oncol, 2009, 27(35):5931-5937.
15. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26(35):5705-5712.
16. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med, 2009, 360(6):563-572.
17. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer, 2010, 46(11):1997-2009.
18. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res, 2008, 68(6):1953-1961.
19. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res, 2009, 69(5):1851-1857.